<DOC>
	<DOCNO>NCT00743028</DOCNO>
	<brief_summary>This randomize , open-label , multicenter crossover study determine oral bioavailability new ABT-263 formulation relative current ABT-263 formulation administer ongoing Phase 1/2a study . Approximately 36 evaluable subject lymphoid malignancy , include chronic lymphocytic leukemia , solid tumor enrol study .</brief_summary>
	<brief_title>Assess Oral Bioavailability New ABT-263 Formulations</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>&gt; =18 year age ; Nonhematologic malignancy hematologic malignancy either relapse refractory standard therapy , fail 5 prior standard therapy know effective therapy exist ; Life expectancy least 90 day ; If clinically indicate , ( e.g. , subject age 70 ) subject must document brain imaging ( MRI CT ) negative subdural epidural hematoma within 28 day prior 1st dose study drug ; ECOG performance score &lt; = 1 ; Adequate bone marrow , renal hepatic function per local laboratory reference range follow : ANC &gt; = 1,000/Âµl ; Platelets &gt; = 100,000/mm3 ; Hemoglobin &gt; = 9.0 g/dL ; serum creatinine &lt; = 2.0 mg/dL calculate creatinine clearance &gt; = 50 ; AST ALT &lt; = 3.0 x ULN ; Bilirubin &lt; = 1.5 x ULN . Gilbert 's Syndrome may Bilirubin &gt; 1.5 x ULN ; aPTT , PT exceed 1.2 x ULN ; Females must surgically sterile , postmenopausal , negative pregnancy test screening ; Females surgically sterile postmenopausal &amp; nonvasectomized male must practice least one follow method birth control : Total abstinence sexual intercourse ( minimum one complete menstrual cycle prior start study drug ) ; Vasectomized partner ; Hormonal contraceptive least 3 month prior study ; Doublebarrier method ( include condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) . History of/clinically suspicious cancerrelated CNS disease ; An allogeneic stem cell transplant . Underlying , predispose condition bleeding/currently exhibit sign bleed . History nonchemotherapy induce thrombocytopenic associate bleed w/i 1 year prior 1st dose . Peptic ulcer disease hemorrhagic esophagitis/gastritis . Active ITP/ history refractory platelet transfusion . Significant history cardiac , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic/hepatic disease . Females pregnant breastfeeding . History active medical condition ( ) affect absorption motility . Positive HIV . Other clinically significant uncontrolled condition ( ) include , limited : active systemic fungal infection ; neutropenic fever w/i 1 wk prior study drug . Steroid therapy w/i 7 day prior 1st dose anticancer intent . Anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal ( except hormone hypothyroidism ERT ) /agonists required suppress serum testosterone level [ e.g . LHRH , GnRH ] , investigational therapy w/i 14 day prior first dose study drug . Biologic agent w/i 30 day prior 1st dose . Anticoagulation therapy/drugs/herbal supplement affect platelet function . Aspirin w/i 7 day prior 1st dose . Grapefruit/grapefruit product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Other hematological non-hematological malignancy</keyword>
</DOC>